APA

Lyden P., Pryor K. E., Coffey C. S., Cudkowicz M., Conwit R., Jadhav A., Sawyer R. N., Claassen J., Adeoye O., Song S., Hannon P., Rost N. S., Hinduja A., Torbey M., Lee J., Benesch C., Rippee M., Rymer M., Froehler M. T., Clarke Haley E., Johnson M., Yankey J., Magee K., Qidwai J., Levy H., Mark Haacke E., Fawaz M., Davis T. P., Toga A. W., Griffin J. H. & Zlokovic B. V. (20191125). Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. : Annals of neurology.

Chicago

Lyden Patrick, Pryor Kent E, Coffey Christopher S, Cudkowicz Merit, Conwit Robin, Jadhav Ashutosh, Sawyer Robert N, Claassen Jan, Adeoye Opeolu, Song Shlee, Hannon Peter, Rost Natalia S, Hinduja Archana, Torbey Michel, Lee Jin-Moo, Benesch Curtis, Rippee Michael, Rymer Marilyn, Froehler Michael T, Clarke Haley E, Johnson Mark, Yankey Jon, Magee Kim, Qidwai Julie, Levy Howard, Mark Haacke E, Fawaz Miller, Davis Thomas P, Toga Arthur W, Griffin John H and Zlokovic Berislav V. 20191125. Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. : Annals of neurology.

Harvard

Lyden P., Pryor K. E., Coffey C. S., Cudkowicz M., Conwit R., Jadhav A., Sawyer R. N., Claassen J., Adeoye O., Song S., Hannon P., Rost N. S., Hinduja A., Torbey M., Lee J., Benesch C., Rippee M., Rymer M., Froehler M. T., Clarke Haley E., Johnson M., Yankey J., Magee K., Qidwai J., Levy H., Mark Haacke E., Fawaz M., Davis T. P., Toga A. W., Griffin J. H. and Zlokovic B. V. (20191125). Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. : Annals of neurology.

MLA

Lyden Patrick, Pryor Kent E, Coffey Christopher S, Cudkowicz Merit, Conwit Robin, Jadhav Ashutosh, Sawyer Robert N, Claassen Jan, Adeoye Opeolu, Song Shlee, Hannon Peter, Rost Natalia S, Hinduja Archana, Torbey Michel, Lee Jin-Moo, Benesch Curtis, Rippee Michael, Rymer Marilyn, Froehler Michael T, Clarke Haley E, Johnson Mark, Yankey Jon, Magee Kim, Qidwai Julie, Levy Howard, Mark Haacke E, Fawaz Miller, Davis Thomas P, Toga Arthur W, Griffin John H and Zlokovic Berislav V. Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. : Annals of neurology. 20191125.